Stanford University
Showing 791-800 of 1,110 Results
-
Masashi Miyauchi
Basic Life Research Scientist, Medicine - Med/Hematology
BioMasashi Miyauchi, MD, PhD, is a physician-scientist specializing in hematology, oncology, immunology, and stem cell biology, with over a decade of experience in clinical hematology and oncology. Dr. Miyauchi's academic career commenced at Kyoto University, where he obtained his MD in Medicine. He furthered his expertise with a PhD in Internal Medicine from The University of Tokyo, Graduate School of Medicine. Following his comprehensive clinical training and professional appointments at The University of Tokyo Hospital, Dr. Miyauchi embarked on a postdoctoral journey at Stanford University in the Nakauchi lab, starting in July 2019.
Dr. Miyauchi's clinical training is extensive, including a Senior Residency in Internal Medicine and a Clinical Fellowship in Hematology and Oncology at The University of Tokyo Hospital. This period was complemented by his participation in a Cancer Professional Training Plan. After completing his clinical fellowship, Dr. Miyauchi has served in various pivotal roles at The University of Tokyo Hospital and The University of Tokyo. His positions as a clinically-focused Project Assistant Professor and Assistant Professor in the Department of Hematology and Oncology have enabled him to contribute significantly to pioneering research and education for the next wave of medical professionals.
In his PhD research, Dr. Miyauchi specialized in the disease modeling of cancers and cancer stem cells, employing cancer patient-specific induced pluripotent stem cells (iPSCs). His work with iPSCs notably includes scalable ex vivo manufacturing of human neutrophils. In his postdoctoral research under the guidance of Dr. Hiromitsu Nakauchi in Genetics at Stanford, Dr. Miyauchi has been concentrating on developing a stable hematopoietic stem cell (HSC) expansion system in both mouse and human models. His research is focused on exploring the potential applications of this expansion system, underlining his commitment to advancing the fields of stem cell biology, regenerative medicine and oncology.
